[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369620-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369620-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-cdks-in-cancer-therapy-advances-in-protacs-and-molecular-glues","Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues","","Essential transcription and cell cycle controllers, CDKs, are frequently dysregulated in human cancers, making them key therapeutic targets. While traditional CDK inhibitors can achieve clinical efficacy, resistance mechanisms and off-target effects limit their impact. Targeted protein degradation strategies, including PROTACs and molecular glues, offer more selective disruption of CDK proteins by engaging degradation pathways rather than only inhibiting kinase activity. This review summarizes clinical and preclinical progress, analyzes the CDK-targeting therapeutic landscape, and discusses benefits, current challenges, and future directions for precision oncology.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-cdks-in-cancer-therapy-advances-in-protacs-and-molecular-glues/369620/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-cdks-in-cancer-therapy-advances-in-protacs-and-molecular-glues/369620.png","ImageObject",300,407,{"name":42,"@type":43},"Putri","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are CDKs important therapeutic targets in cancer?","Question",{"text":63,"@type":64},"CDKs are essential regulators of cell cycle progression, and their dysregulation is a defining feature of many cancers. This makes CDKs central drivers of tumor growth and progression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limitations affect traditional CDK inhibitors?",{"text":68,"@type":64},"Traditional CDK inhibitors can be therapeutically effective, but they often face limitations from resistance mechanisms and off-target effects.",{"name":70,"@type":61,"acceptedAnswer":71},"How do PROTACs and molecular glues help target CDKs differently from kinase inhibition?",{"text":72,"@type":64},"PROTACs recruit an E3 ubiquitin ligase to a target protein to trigger destruction via the ubiquitin-proteasome system. Molecular glues promote protein-protein interactions that enable focused breakdown of disease-related proteins, offering more complete blockade of oncogenic signaling.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369620,1790564832,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","npj | precision oncology Review  \n\n| Published in partnership with The Hormel Institute, University of Minnesota |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s41698-025-00931-8](https://doi.org/10.1038/s41698-025-00931-8) |  |  |\n| Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues\u003Cbr> Check for updates |  |  |\n| Hany E. Marei1 , Khaled Bedair2, Anwarul Hasan3, Layla Al-Mansoori4, Alice Gaiba5, Andrea Morrione6, Carlo Cenciarelli5 & Antonio Giordano6,7 |  |  |\n| Essential transcription and cell cycle progression controllers are CDKs, whose dysregulation is adeﬁning trait of many human cancers. CDKs have grown to be very crucial therapeutic targets in cancer. Although traditional CDK inhibitors have demonstrated therapeutic efﬁcacy, they frequently encounter limitations due to resistance mechanisms and off-target effects. Recent developments in targeted protein degradation, like proteolysis-targeting chimeras (PROTACs) and molecular glues, offer creative ways to destroy CDK proteins speciﬁcally. These techniques reduce scaffolding activities and slow down kinase activity, hence more completely blocking oncogenic CDK signaling. This paper highlights the clinical and preclinical developments of PROTACs and molecular glues, investigates the current CDK-targeting therapeutic landscape, and studies the molecular basis ofCDK dysregulation in cancer. We also address their beneﬁts over conventional inhibitors, current issues, and possibilities for inclusion into precision oncology. These new approaches taken together represent a change in CDK-targeted cancer therapy. |  |  |\n| Background\u003Cbr>Comprising consecutive phases—G1, S, G2, and M—the cell cycle is a vital process controlling cell development and division that guarantees exact DNA replication and mitosis. CDKs and their matching cyclin subunits, which are activated by external signals—especially growth factor-initiated signaling pathways inﬂuencing particular CDK-cyclin complexes—meticulously control eukaryotic cells’ advancement through these stages1 (Fig. 1). Furthermore, DNA damage-induced cell cycle checkpoints could lower CDK activity to maintain genomic integrity2.\u003Cbr>Disordered control of the cell cycle is a characteristic of cancer, often caused by genetic abnormalities in CDKs, cyclins, or upstream signaling elements3–5. This imbalance leads to uncontrolled cell growth and tumor progression. As a result, CDKs have become interesting therapeutic targets, which has prompted the development of several small molecules CDK inhibitors to treat human malignancies2.\u003Cbr>Creative protein degradation techniques such as proteolysis-targeting chimeras(PROTACs)and molecular glues provide different ways to inhibit | CDKs and other oncogenic proteins. Bifunctional compounds called PROTACs bring an E3 ubiquitin ligase to a target protein, causing its destruction using the ubiquitin-proteasome mechanism. Especially in targeting complex proteins like BRD4, they have shown promising efﬁcacy in preclinical cancer models6. Small molecules called molecular glues increase protein-protein connections, therefore enabling the focused breakdown of disease-related proteins, such as those interactingwith cereblon, represented by lenalidomide7. These creative approaches have shown therapeutic promise in neurological diseases, cancer, and autoimmune disorders8.\u003Cbr>Using amore basic chemical design, molecular glues could use the cell’s naturalbreakdown mechanismsto solve some PROTAC constraints9. Apart from small molecules, non-small molecule strategies such as CRISPR-based gene editing and RNA interference (RNAi) offer precise or transient suppression ofCDK activity, hence reducing off-target consequences in cancer models10. By enabling the control of previously “undruggable” targets and offering fresh routes for exact cancer therapy, these creative approaches are changing the therapeutic scene. |  |\n\n1Department of Cytology and Histology, Faculty of Veterinary Medicine,","cbCaijXwdOTndeZO","https://ap.wps.com/l/cbCaijXwdOTndeZO","pdf",1306140,17,"English","# Background\n## Cell cycle control and checkpoints\n## CDK dysregulation in cancer\n# Targeted protein degradation approaches\n## PROTACs and E3 ubiquitin ligases\n## Molecular glues and cereblon-based interactions\n## Beyond small molecules: CRISPR and RNA interference\n# Cell cycle proteins and cancer progression\n## CDK4/6-RB pathway and regulators","[{\"question\":\"Why are CDKs important therapeutic targets in cancer?\",\"answer\":\"CDKs are essential regulators of cell cycle progression, and their dysregulation is a defining feature of many cancers. This makes CDKs central drivers of tumor growth and progression.\"},{\"question\":\"What limitations affect traditional CDK inhibitors?\",\"answer\":\"Traditional CDK inhibitors can be therapeutically effective, but they often face limitations from resistance mechanisms and off-target effects.\"},{\"question\":\"How do PROTACs and molecular glues help target CDKs differently from kinase inhibition?\",\"answer\":\"PROTACs recruit an E3 ubiquitin ligase to a target protein to trigger destruction via the ubiquitin-proteasome system. Molecular glues promote protein-protein interactions that enable focused breakdown of disease-related proteins, offering more complete blockade of oncogenic signaling.\"}]","Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues | PDF",1790183706,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4810df3f622e0018e1bb5d6cb81cf74.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85cf79f9511157eaf7a798c2075d778a.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5f9702e4f54935deb3c532019284fd2.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a59da095f98573c4f2f8da6edbed7d4.webp",980,1301]